Cryopreserved MMUD BM With PTCy for Hematologic Malignancies
Status:
Not yet recruiting
Trial end date:
2024-03-01
Target enrollment:
Participant gender:
Summary
This is a multi-phase, multi-center, single arm, prospective study designed to establish the
safety and efficacy of human leukocyte antigen (HLA)-mismatched unrelated cryopreserved
deceased donor bone marrow transplantation (BMT) with post-transplantation cyclophosphamide
for patients with hematologic malignancies.
Phase:
Phase 1
Details
Lead Sponsor:
Center for International Blood and Marrow Transplant Research